RJ Shah & Company schedules board meeting on 24 July to approve Q1 FY2026 results

What RJ Shah & Company announced

RJ Shah & Company Ltd (BSE: 509845) informed the Bombay Stock Exchange that its Board of Directors will convene on 24 July 2026. The sole agenda item disclosed is the consideration and approval of the un‑audited quarterly financial results for the period ended 30 June 2026. The intimation was filed on 18 July 2026.

Board meeting details

The notice states that the meeting will be held in accordance with the Companies Act, 2013 and the company’s Articles of Association. No other business items were mentioned. The filing does not provide the time or venue of the meeting, nor does it list the directors who will attend.

Quarterly results context

The filing is a standard regulatory requirement that precedes the public release of quarterly numbers. While the company confirms that the results are un‑audited, it does not disclose any quantitative data such as revenue, profit, or earnings per share. Consequently, investors cannot assess performance from this notice alone; they must await the formal results announcement, which typically follows board approval.

Key facts at a glance

Why this matters for investors

The board’s approval is a prerequisite for the company to publish its quarterly numbers on the stock exchanges and in its statutory filings. Once approved, the results become part of the public record and can influence analysts’ assessments and investors’ expectations. Because the results are still unaudited, they may be subject to adjustments after the audit, but the board’s sign‑off signals that the figures are ready for dissemination. No immediate dilution or capital‑raising activity is indicated in the notice.

Conclusion

RJ Shah & Company’s board will meet on 24 July 2026 to approve its unaudited Q1 FY2026 financials. The filing, made on 18 July, does not reveal any performance metrics, so investors will need to wait for the subsequent results announcement to gauge the company’s financial health. No further corporate actions are disclosed at this stage.